Introduction to NDC Codes
The National Drug Code (NDC) is a unique identifier assigned to each drug product by the FDA. The NDC code 57237-0158 is associated with a specific formulation of the drug Ondansetron, which is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery.
Drug Overview: Ondansetron
Ondansetron is a serotonin 5-HT3 receptor antagonist, commonly used to manage nausea and vomiting. It is available in various formulations, including orally disintegrating tablets, which are convenient for patients who have difficulty swallowing traditional tablets[5].
Market Context
The pharmaceutical market is dynamic and influenced by several factors, including regulatory changes, new drug approvals, and economic conditions.
Specialty Pharmaceuticals and Price Inflation
Specialty pharmaceuticals, which include drugs for complex or chronic conditions, are a significant driver of drug price inflation. According to Vizient, Inc., the projected increase in drug prices for 2024 is 3.8%, largely driven by specialty pharmaceuticals. While Ondansetron is not classified as a specialty drug, overall market trends can impact its pricing[2].
Biosimilars and Generic Competition
The introduction of biosimilars and generic versions of drugs can significantly impact market prices. For example, biosimilars for drugs like Humira are expected to gain market share, reducing the dominance of brand-name drugs. However, Ondansetron, being a generic drug itself, is less likely to be directly affected by biosimilar competition but may see price stability due to generic market dynamics[2].
Price Projections
Current Market Pricing
As of the latest data, the pricing for Ondansetron orally disintegrating tablets is influenced by the generic market. Generic drugs typically have lower prices compared to their brand-name counterparts. The NDC code 57237-0158, associated with Rising Pharma Holdings, Inc., would be priced competitively within the generic market segment[5].
Future Price Trends
Given the overall trend of moderate price inflation in the pharmaceutical sector, it is likely that the price of Ondansetron will experience minimal to moderate increases. Here are some key points to consider:
- Generic Market Stability: Generic drugs like Ondansetron tend to have stable prices due to competition among multiple manufacturers.
- Inflation and Economic Factors: General inflation and economic conditions can lead to slight price increases, but these are typically managed within a narrow range.
- Regulatory and Supply Chain Factors: Changes in regulatory policies or supply chain disruptions could potentially impact prices, but these are less likely to significantly affect a well-established generic drug like Ondansetron.
Statistical Insights
The opioids drugs market, while not directly related to Ondansetron, provides a broader context of pharmaceutical market trends. The opioids market is projected to grow at a CAGR of 4.54% from 2023 to 2029, indicating a stable growth trajectory for pharmaceuticals in general. However, this growth rate is not directly applicable to Ondansetron but suggests a stable market environment[4].
Utilization and Demand
Clinical Use
Ondansetron is widely used in clinical settings for preventing nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Its demand is consistent due to its efficacy and the ongoing need for antiemetic therapy in these patient populations.
Market Share
As a generic drug, Ondansetron competes with other generic versions. The market share is distributed among various manufacturers, with no single entity dominating the market. This competition helps maintain price stability.
Regulatory Environment
FDA Oversight
The FDA plays a crucial role in regulating drug prices and ensuring the quality and safety of drug products. The New NDC Directory, updated daily, includes comprehensive information on all listed drugs, including Ondansetron, ensuring transparency and compliance with regulatory standards[1].
Conclusion
The price projections for the drug NDC: 57237-0158, associated with Ondansetron orally disintegrating tablets, are likely to remain stable with minimal to moderate increases. Here are the key takeaways:
- Stable Generic Market: The generic nature of Ondansetron ensures competitive pricing.
- Moderate Inflation: General pharmaceutical market trends suggest moderate price inflation.
- Regulatory Stability: FDA oversight and the New NDC Directory ensure compliance and transparency.
- Consistent Demand: Ondansetron's clinical use ensures consistent demand.
Key Takeaways
- Price Stability: Expected due to generic market competition.
- Moderate Inflation: General market trends indicate minimal price increases.
- Regulatory Compliance: Ensured by FDA oversight and the New NDC Directory.
- Consistent Demand: Driven by clinical use in preventing nausea and vomiting.
FAQs
What is the NDC code 57237-0158 associated with?
The NDC code 57237-0158 is associated with Ondansetron orally disintegrating tablets, a generic drug used to prevent nausea and vomiting.
How does the generic market impact the price of Ondansetron?
The generic market ensures competitive pricing for Ondansetron, leading to stable and generally lower prices compared to brand-name drugs.
What are the key factors influencing the price of Ondansetron?
Key factors include generic market competition, overall pharmaceutical market trends, regulatory environment, and economic conditions.
How does the FDA regulate drug prices and quality?
The FDA regulates drug prices and quality through oversight and the maintenance of the New NDC Directory, ensuring transparency and compliance.
What is the projected growth rate for the pharmaceutical market?
The pharmaceutical market, including segments like opioids, is projected to grow at moderate rates, such as a CAGR of 4.54% for the opioids market from 2023 to 2029.
Sources
- NDC Directory - YouTube
- Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals - Vizient Inc.
- 57237-0078 Ondansetron - CanMED: NDC - SEER Cancer
- Opioids Drugs Market- Global Industry Analysis and Forecast (2023-2029) - Maximize Market Research
- Label: ONDANSETRON tablet, orally disintegrating - DailyMed
